Giles Platford/LinkedIn
Dec 12, 2025, 09:34
Giles Platford on Baby Big: Plasma-Derived Drug Against Infant Botulism
Giles Platford, President, Plasma-Derived Therapies Business Unit at Takeda and Chair of the Global Executive Board at PPTA, shared on LinkedIn:
”Plasma-derived therapies are often the only effective treatment for patients with certain rare and complex, chronic conditions.
One case in point is infant botulism: in partnership with the California Department of Public Health, on a non-profit basis, Takeda produces the only FDA-approved treatment for this condition, Baby Big.
The recent outbreak of infant botulism in the U.S. has put a fine point on the importance of this therapy.
Learn more in this story from The Independent”
Stay updated with Hemostasis Today.
-
Jun 23, 2026, 16:48Khusboo Kumari: Laboratory Skills in Hematology
-
Jun 23, 2026, 16:45Advancing Sickle Cell Disease Research Through Community Support – ASH
-
Jun 23, 2026, 16:35Which Thrombophilia Tests Really Matter? – ICHCC
-
Jun 23, 2026, 16:26Ifeanyichukwu Ifechidere: A Prolonged APTT Is Not Always a Bleeding Disorder
-
Jun 23, 2026, 15:36Arun V. J.: Transforming Transfusion Medicine Through Leadership Development
-
Jun 23, 2026, 15:32Wolfgang Miesbach: Liver Organoids Advance the Future of AAV Gene Therapy Safety Testing
-
Jun 23, 2026, 15:27Shadi Tabibian: A New Era in von Willebrand Disease Treatment
-
Jun 23, 2026, 15:13Ibré Gallardo: Shifting Paradigms in AFIB Therapeutics
-
Jun 23, 2026, 14:26James Crowley: The Hidden Burden of Atrial Fibrillation